+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

Notch Signaling Pathway Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Notch Signaling Pathway Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Galectin Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Galectin Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
ATPase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

ATPase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Gamma Secretase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Gamma Secretase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CD152 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CD152 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CCR3 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CCR3 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Beta-2 Receptors Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Beta-2 Receptors Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CCR5 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CCR5 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
PI3K inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

PI3K inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
From
Eg5 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Eg5 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
RON (Recepteur d'origine Nantais) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

RON (Recepteur d'origine Nantais) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Heat shock protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Heat shock protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Sphingosine 1-Phosphate (S1P) Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Sphingosine 1-Phosphate (S1P) Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Transforming growth factor beta inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Transforming growth factor beta inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
TIM-3 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

TIM-3 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CD 3 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CD 3 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
CD 33 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

CD 33 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more